Study finds drug for reducing lipid in patients with hypertriglyceridemia

Published On 2024-04-09 02:30 GMT   |   Update On 2024-04-09 08:59 GMT
Advertisement

A study presented at the 2024 American College of Cardiology's Annual Scientific Session & Expo and published in the New England Journal of Medicine, revealed an experimental treatment that could further lower triglycerides in the blood of patients at high cardiovascular risk.

Hypertriglyceridemia, or high levels of lipids (fats) in the blood, increases the risk of heart attack, stroke and acute pancreatitis. Currently available medications, including statins, fibrates, and prescription omega-3 fatty acids, typically lower triglyceride levels by anywhere from below 10% to up to 40%.

In the study, researchers conducted a randomized trial on 154 adults on lipid-lowering therapy with moderate or severe hypertriglyceridemia to receive either 50mg olezarsen, 80mg olezarsen or placebo. Olezarsen is an antisense oligonucleotide that inhibits APOC3, a gene associated with higher levels of triglycerides, by targeting its mRNA. The subcutaneous medication was administered every four weeks, for a period of a year.

The results showed that olezarsen reduced triglyceride levels by 49% at the 50mg dose and 53% at the 80mg dose, compared with placebo. The experimental drug also reduced apolipoprotein B and non-HDL cholesterol, which are important in plaque formation, by 18 to 18.5% and 23% to 25%, respectively.

“These findings indicate that targeting APOC3 mRNA is a promising new pathway for lowering triglycerides and potentially reducing the risk of heart attack and stroke,” said corresponding author Brian Bergmark, MD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital.

Reference: Brian A. Bergmark, M.D., Nicholas A. Marston, M.D., M.P.H., Thomas A. Prohaska, M.D., Ph.D., Veronica J. Alexander, Ph.D., André Zimerman, M.D., Ph.D., Filipe A. Moura, M.D., Ph.D., Sabina A. Murphy, M.P.H., Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk; Journal: the New England Journal of Medicine; DOI: 10.1056/NEJMoa2402309



Full View
Tags:    
Article Source : Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News